Evidence map›Paper›PMID 34956100›Full record

ArticleFrontiers in endocrinology2021

Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications.

Iuliu Sbiera, Stefan Kircher, Barbara Altieri, Kerstin Lenz, Constanze Hantel, Martin Fassnacht, Silviu Sbiera, Matthias Kroiss

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00669266 (Investigation of the Tumorigenesis of Adrenal Tumors and Evaluation of New Therapeutic Options - Untersuchungen Zur Tumorgenese Von Nebennierentumoren Und Evaluation Neuer Therapieoptionen), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00669266 recruitingnot on this map

Investigation of the Tumorigenesis of Adrenal Tumors and Evaluation of New Therapeutic Options - Untersuchungen Zur Tumorgenese Von Nebennierentumoren Und Evaluation Neuer Therapieoptionen

TypeobservationalSponsorUniversity of WuerzburgRan2002 to 2032Enrolled500ConditionsAdrenal Tumors, Adrenocortical Carcinoma, Cushing Syndrome, Conn Syndrome
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Iuliu SbieraDepartment of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, Germany.
Stefan KircherInstitute of Pathology, University of Würzburg, Würzburg, Germany.
Barbara AltieriDepartment of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, Germany.
Kerstin LenzDepartment of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, Germany.
Constanze HantelDepartment of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zürich (USZ) and University of Zürich (UZH), Zürich, Switzerland.
Martin FassnachtDepartment of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, Germany.
Silviu SbieraDepartment of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, Germany.
Matthias KroissDepartment of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, Germany.
Universitätsklinikum Würzburg · DEUniversity of Würzburg · DEComprehensive Cancer Center Mainfranken · DEUniversity Hospital Carl Gustav Carus · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adrenocortical carcinoma (ACC) is a rare endocrine malignancy and treatment of advanced disease is challenging. Clinical trials with multi-tyrosine kinase inhibitors in the past have yielded disappointing results. Here, we investigated fibroblast growth factor (FGF) receptors and their pathways in adrenocortical tumors as potential treatment targets. We performed real-time RT-PCR of 93 FGF pathway related genes in a cohort of 39 fresh frozen benign and malignant adrenocortical, 9 non-adrenal tissues and 4 cell lines. The expression of FGF receptors was validated in 166 formalin-fixed paraffin embedded (FFPE) tissues using RNA

Indexed as

Adrenal Cortex NeoplasmsAdrenocortical CarcinomaAdultBiomarkers, TumorFemaleHumansMaleMiddle AgedReal-Time Polymerase Chain ReactionReceptor, Fibroblast Growth Factor, Type 1Receptor, Fibroblast Growth Factor, Type 4Survival RateBiomarkers, TumorFGFR1 protein, humanFGFR4 protein, humanReceptor, Fibroblast Growth Factor, Type 1Receptor, Fibroblast Growth Factor, Type 4adrenocortical tumorsFGF-pathwayFGFRnormal adrenal glandspatient survivalRNA ExpressionRNAScopeunsupervised clustering

Identifiers

PMID34956100
PMCPMC8699171
OpenAlexW4200347957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.